Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
768.530.22%
QQQ
719.650.1%
BTC/USD
78714.050.4757%
DIA
530.240.72%
GLD
403.300.85%
TLT
81.940.33%

Citius Pharmaceuticals Inc

CTXRNASDAQ
Trade with Public
Trade with Public
$0.5877
-0.0143-2.38%
At close: Sep 3, 5:00 PM EST
$0.6100
0.0081.33%
Pre-Market: 4:29 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Citius Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Citius Pharmaceuticals (CTXR).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT+719.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 18, 2026HC Wainwright & Co.Swayampakula RamakanthAssumesBuy$4
Mar 11, 2026D. Boral CapitalJason KolbertMaintainedBuy$6
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Lowers Price Target to $6

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and lowers the price target from $9 to $6.
Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $9 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved